Zia Durrani

#OUCVGR 🔥Superb review on Cardiometabolic risk in South Asians by Dr. Kevin Shah from UC Irvine today at a very well attended OU CV GR 🔥Thank you @KevinShahMD for sharing your slides ⬇️ Follow 🧵 @OUCollegeofMed @iamritu @hvanspall @VietHeartPA @purviparwani @DrMarthaGulati @HeartOTXHeartMD @ShashankSinhaMD @noshreza @JasonKatzMD

New science🚨 Early initiation & uptitration of Sac/Val💊 vs ACEI/ARB in pts w/AHF led to ⬆️NT-proBNP reduction w/o AEs. Sac/Val💊 uptitration linked to: ⬇️kidney dysfunction ⬆️NYHA class. Results support timely Sac/Val initiation & thoughtful uptitration🚀 🧵

HFrEF in 2026 Most common Rx is use still ACEI/ARB+BB, despite Class 1 recommendation for quadruple GDMT ACEI/ARB+BB ➡️ ARNI+BB+MRA+SGLTi Extends median survival: 6.3 years 75.6 months 2300 days 55,188 hours 3,311,280 minutes 💊s cost extra $70 per month Worth it?

📚 Journal Club Recap Two weeks ago, we discussed: “Bleeding Risk with Apixaban vs. Rivaroxaban in Acute Venous Thromboembolism” Published in the New England Journal of Medicine 🔗 nejm.org/doi/full/10.10…

🚨 FDA approved #Orforglipron (#Foundayo), Eli Lilly’s new once-daily oral GLP-1 pill for obesity. ✅ Can be taken any time of day, with or without food or water (unlike other oral GLPs) ✅average weight loss: 11% of their body weight A game-changer for weight loss! 💊 #Obesity​​​​​​​​​​​​​​​​ 📎 prnewswire.com/news-releases/…

Register now for the 2026 OU Health Cardiovascular Symposium! All healthcare professionals welcome! This one‑day event will explore the current landscape and future directions of cardiovascular care with opportunities for community building and collaboration. Link in bio!

#OUCVGR 🔥 Excited to welcome Dr. Danita Sanborn from MGH to virtual OU CV GR tomorrow 04/02/26 at 7.15 am CT 🔥Dr. Sanborn was co-chair for ASE Guidelines on Diastolic Function & HFpEF 🔥Join us⬇️ oklahoma.zoom.us/j/96938491268?… @OUCollegeofMed @ASE360 @DavidWienerMD @purviparwani @JaeKOh2 @iamritu @TWeickert78 @PWesslyMD @alex1708ander @Hragy @DrHaloot @ShashankSinhaMD @argulian @HeartOTXHeartMD @NadeenFaza

🔥 OU Cardiology showing up STRONG at #ACC26 🔥 From the clinics to the conference stage — our fellows and IM residents are here, representing, learning, and leading. This is what the future of cardiology looks like 💪 #ACCFellows #Cardiology #OUCardio

@JosephSassineMD @OUCollegeofMed Congratulations Dr Sassine on your well deserved promotion

Happy to share news of my upcoming promotion to Associate Professor of Medicine at @OUCollegeofMed starting this July. Grateful to my mentors and colleagues who helped make it happen, including those who wrote letters of support for my promotion.

🚨 #ACC26 is NOT a meeting… it’s a movement! Big trials. Big ideas. Big connections. I’ll be live from the frontlines as the #ACC26 Social Media Ambassador 👨🏻‍✈️bringing you the 🔥 📰you don’t want to miss Let’s go New Orleans 🎷 @ACCinTouch @JACCJournals @ACCmediacenter

🚨 Fellows. Residents. Early career cardiologists — listen up. #ACC26 is NOT just a conference. It’s a career accelerator 🚀 If you show up right, it can change your trajectory. Here’s how to MAXIMIZE 🎯every minute 👇 @ACCinTouch @JACCJournals @ACCmediacenter

🚨 Post-ROSC Pearl: Code-dose epi (1mg IV) wears off in ~3 minutes. That’s your rearrest window. Have push-dose pressors at the bedside BEFORE the crash comes. Don’t wait for the monitor to tell you what you already know. Have a listen for more pearls: coreem.net/podcast/episod…

#OUCVGR 🔥Delighted to welcome Dr. Jeremy Slivnick from University of Chicago to Virtual OU CV Grand Rounds on March 26, 2026 at 7.15 am. 🔥 Join us for an update on multimodality imaging on Cardiac Amyloidosis ⬇️ oklahoma.zoom.us/j/95144325342?… @OUCollegeofMed @ShashankSinhaMD @JasonKatzMD @HeartOTXHeartMD @dranulala @DrJMarine @AnkurKalraMD @iamritu

De-Prescribing: Balancing Risks and Benefits ⚖️ Most patients with a de-prescribing opportunity also have a prescribing one — but we’re overlooking the nuance. For more listen here and tune into the full episode 517 wherever you stream your podcasts! 📻

Clopidogrel is superior to aspirin for cardiac outcomes beyond 1-year up to 5-years. Results from the STOPDAPT-2 ACS and STOPDAPT-2 Total Cohort. Should it be a lifelong maintenance therapy? @HirotWatanabeMD @MNatsuaki @KoYamamoto7 ahajrnls.org/3PlxLhD

Can AI read an ECG like a cardiologist - from just an image? We built ECG-GPT, a vision-text transformer that generates complete diagnostic reports directly from photos of 12-lead ECGs Now out in @ESC_Journals #EHJDigitalHealth Kudos to @aakhunte & @Veer_Sangha_ for leading this @cards_lab 🧵

Cardiac #amyloidosis occurs when an abnormal protein called amyloid builds up in the 🫀. As a result, the 🫀 becomes thick, & doesn't fill or pump well. Explore #CardioSmart hub for resources to help guide discussions w/ patients: bit.ly/4cMlMTX #AmyloidosisAwareness

One of the most meaningful evolutions in the 2026 ACC/AHA dyslipidemia guideline is the continued elevation of CAC as a central tool in preventive decision-making. We have come a long way. 1. In the 2013 guidelines, CAC was effectively sidelined. 2. By 2019, it re-emerged as a decision aid. 3. In 2026, it is now clearly embedded in the framework of risk assessment, treatment initiation, and treatment intensity. Two messages stand out. 1. First, CAC has become the preferred decision aid when treatment decisions are uncertain. This is not an uncommon situation. In real-world practice, uncertainty is the rule rather than the exception, especially in borderline or intermediate-risk individuals. #PowerOfZero provides a clear distinction who is and not at risk that for the decision whether lipid-lowering therapy should be initiated. 2. Second, the guideline goes beyond initiation. CAC is increasingly used to guide the intensity of therapy. Increasing plaque burden corresponds to progressively more aggressive LDL targets and therapeutic strategies. For example, individuals with CAC ≥300–1000 are recommended to pursue LDL reduction strategies approaching secondary prevention intensity, reflecting event rates comparable to treated ASCVD populations. This is a MAJOR shift. CAC is no longer simply a tie-breaker for statin decisions. It is evolving into a disease-guided framework for preventive intensity. From a practical standpoint, this matters.Risk equations estimate probability. CAC visualizes disease. 1. When uncertainty exists, seeing the burden of atherosclerosis often changes the conversation for both clinician and patient. 2. It also aligns therapy more closely with biology (GREATER DISEASE, MORE INTENSE THE TREATMENT) rather than risk-factor projections alone. IN 2026. CAC has moved from the margins of guidelines to the center of preventive cardiology. For clinicians, that represents one of the most practical advances in translating risk assessment into actionable care. Congrats @rblument1 @RonBlankstein @DrMichaelShapir & rest of the guideline authors @AJPCardio @ASPCardio @MichaelJBlaha @Sadeer_AlKindi @HMethodistCV

ACC/AHA & 9 other leading medical associations released an updated clinical guideline for managing #dyslipidemia. About 1 in 4 US adults has high LDL-C, raising risk of heart attack & stroke. Get the details in #JACC: jacc.org/doi/10.1016/j.… #ClinicalGuidelines #cvLipids #ASCVD

2026 ACC/AHA/AACVPR/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Dyslipidemia ahajrnls.org/4saq5NS